Longitudinal serum testosterone levels (T) in long-term testicular cancer survivors (TCSs) in relation to testicular cancer (TC) treatment, aging, and TC diagnosis itself.

Authors

null

Mette Sprauten

OUS, The Norwegian Radium Hospital, Oslo, Norway

Mette Sprauten , Milada Cvancarova , Sophie D. Fossa , Marianne Brydoy , Hege Sagstuen Haugnes , Jan Oldenburg

Organizations

OUS, The Norwegian Radium Hospital, Oslo, Norway, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway, Haukeland University Hospital, Bergen, Norway, Institute of Clinical Medicine, University of Tromsoe, Tromsoe, Norway

Research Funding

No funding sources reported
Background: Low T may increase the risk of cardiovascular disease, osteoporosis, and reduced quality of life. T might be reduced by TC, its treatment, ageing, and particularly their combination. Methods: T was retrieved from 311 TCSs after orchiectomy and prior to subsequent management with either surveillance/surgery only (S), radiotherapy (RT) or cisplatin based chemotherapy (CT). Human Chorionic Gonadotropin (hCG) was available for 211 TCSs. T was reassessed at surveys performed 9 (S9) and 18 years (S18) after treatment. T values were categorized into quartiles according to cut-off values derived from 570 healthy controls (C) for each decadal age group. Statistical associations were assessed with Chi2 tests. Results: In TCSs about to receive RT or CT, T and hCG were higher when compared to those subsequently managed by S. TCSs were more likely to belong to the lowest T quartile, more so with increasing treatment intensity (table). The proportions of TCSs belonging to the corresponding T quartiles displayed no significant changes from S9 to S18. Conclusions: TCSs had lower T than C of similar age already after orchiectomy, possibly related to removal of the affected testicle and/or testicular dysgenesis syndrome. TCSs who were to receive RT or CT had slightly increased T when compared to S, probably due to hCG stimulation. T reduction by RT or CT has been described previously but rarely in longitudinal studies. Of note, longitudinal assessment of T without comparison to C might result in overestimation of the treatment burden. Relatively stable age adjusted T levels from S9 to S18 for the TCSs independent of treatment are encouraging.
C: n=570,
(100%)
S: n=69,
(100%)
RT: n=133,
(100%)
CT: n=109,
(100%)
Pretreatment
<25% 139 (24.4) 39 (56.5) 62 (46.6) 42 (38.5)
>75% 141 (24.7) 3 (4.3) 18 (13.5) 18 (16.5)
OR(95%CI) Referent (R) 13.2 (4.0- 43.7) 3.5 (2.0- 6.2) 2.4 (1.3- 4.3)
S 9
<25% 139 (24.4) 28 (40.6) 61 (45.9) 59 (54.1)
>75% 141 (24.7) 9 (13.0) 12 (9.0) 12 (11.0)
OR(95%CI) R 3.2 (1.4- 7.0) 5.2 (2.7- 10.0) 5.0 (2.6- 9.7)
S18
<25% 139 (24.4) 26 (37.7) 61 (45.9) 67 (61.5)
>75% 141 (24.7) 6 (8.7) 9 (6.8) 10 (9.2)
OR(95%CI) R 4.4 (1.8- 11.0) 6.9 (3.3- 4.4) 6.8 (3.4- 13.7)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer

Track

Genitourinary Cancer

Sub Track

Other GU Cancer

Citation

J Clin Oncol 30, 2012 (suppl; abstr 4637)

DOI

10.1200/jco.2012.30.15_suppl.4637

Abstract #

4637

Poster Bd #

9D

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Genitourinary Cancers Symposium

Longitudinal assessment of cognitive functioning in testicular germ cell tumor survivors.

First Author: Zuzana Orszaghova

First Author: Marcin W Wojewodzic